B & J Group

Warning LetterOpen

United StatesFEI 3010096700Issued Jan 19, 2023Division of Pharmaceutical Quality Operations I

View Letter

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3010096700.

Violations3

Issue DateJan 19, 2023

Product TypeDrugs

StatusOpen

Letter Details

Firm: B & J Group
Location: United States
FEI Number: 3010096700
Country: United States
Issue Date: January 19, 2023
Issuing Office: Division of Pharmaceutical Quality Operations I
Product Type: Drugs
Status: Open

Summary

Based on limited metadata, B & J Group received an FDA Warning Letter on January 19, 2023, regarding drug products, with three identified violations. Without access to the full letter text or specific subject matter details, the exact nature of the violations cannot be determined from the available information. The warning falls under FDA's drug regulatory authority, though the specific issuing office is not documented in this metadata summary.

B & J Group FDA Warning Letter, January 19, 2023